Mononuclear phagocytic cells such as monocytes, macrophages and dendritic cells are at the vanguard of our immune system. Harnessing the capabilities of these cells has tremendous potential for fighting disease.
Rather than reprogramming at the level of DNA or RNA, researchers are now using PODS® sustained-release proteins to efficiently reprogram the proteome directly. With 70% of cells reprogrammed in 24 hours, no expansion is needed.
Whether you are developing new therapies or simply delving into the mechanisms of the immune system, PODS® can help you with your quest.
Isolating EVs in a form compatible with downstream next-generation sequencing (NGS), particularly for small RNA analysis, can be technically challenging. But using the right kits to process the samples, many different groups have now developed an efficient workflow that is generating valuable EV microRNA data.
We explore the status of CAR T-cell therapy in the treatment of solid tumors, possible causes of failure, potential solutions, and the progress of CAR T-cell therapy for solid tumors and discuss the possible significance of CAR T-cell therapy for cancer treatment in the future.
CAR-T has been revolutionary, but as an autologous therapy, it is slow and costly. Allogeneic CAR-T cells, known as iNKTS, are now in development and may offer a rapid, cheaper (and perhaps more effective) off-the-shelf solution.
Targeted protein degradation (TPD) is an emerging technique used to study cellular processes and develop new therapies. Introduced in 1999, TPD works by breaking down specific proteins using either the proteasomal or lysosomal pathways. Most current TPD methods, such as PROTACs, molecular glues, Trim-Away, and SNIPERs, depend on the ubiquitin-proteasome system (UPS) and are primarily designed to target proteins inside cells.
When presented with cancer cells, our cytogeneticists often see tiny chromosomal structures known as double minutes. What are these, how are they formed, and what is their importance?
Macrophages are key immune cells that constantly identify and remove emerging cancers. Unfortunately, some cancer cells slip under the macrophage radar. When these immuno-escaped cancer cells develop the ability to control macrophages, cancers can become enabled to metastasise. However, this reliance on macrophages could provide therapeutic opportunities.
Often overlooked, matrix stiffness is hugely important to the behaviour of cells. A recent study of prostate cancer cells using gels of varying stiffness reveals mechanistic insights.
Complex models of the bone marrow tissue, capable of replicating functional niches that maintain multipotent haemopoietic stem cells, are on the horizon. These models will enable more realistic and informative in-vitro studies of drugs for haematological diseases as well as assessing the myelotoxicty of treatments targeted at other tissues.
